Cabaletta Bio, Inc. (CABA)

NASDAQ: CABA · IEX Real-Time Price · USD
10.66
-1.90 (-15.13%)
At close: Jun 14, 2024, 4:00 PM
10.45
-0.21 (-1.97%)
After-hours: Jun 14, 2024, 7:30 PM EDT
-15.13%
Market Cap 514.63M
Revenue (ttm) n/a
Net Income (ttm) -76.87M
Shares Out 48.28M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,729,081
Open 13.35
Previous Close 12.56
Day's Range 10.00 - 13.50
52-Week Range 9.52 - 26.35
Beta 2.47
Analysts Strong Buy
Price Target 33.88 (+217.82%)
Earnings Date Aug 8, 2024

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 118
Stock Exchange NASDAQ
Ticker Symbol CABA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price forecast is $33.88, which is an increase of 217.82% from the latest price.

Price Target
$33.88
(217.82% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 –

1 day ago - GlobeNewsWire

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials –

4 weeks ago - GlobeNewsWire

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...

4 weeks ago - GlobeNewsWire

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ tria...

3 months ago - GlobeNewsWire

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

3 months ago - GlobeNewsWire

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

4 months ago - GlobeNewsWire

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

4 months ago - GlobeNewsWire

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

5 months ago - GlobeNewsWire

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

7 months ago - GlobeNewsWire

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Shares of Cabaletta Bio Inc. CABA, Gracell Biotechnologies Inc. GRCL and other smaller biotech companies involved in developing CAR-T cell therapies plunged Tuesday after the Food and Drug Administrat...

7 months ago - Market Watch

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients...

7 months ago - GlobeNewsWire

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an...

7 months ago - Business Wire

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

8 months ago - GlobeNewsWire

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapi...

9 months ago - GlobeNewsWire

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

10 months ago - GlobeNewsWire

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

– Received second IND application clearance for CABA-201 in myositis as well as Fast Track Designation in SLE and LN –

11 months ago - GlobeNewsWire

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences –

11 months ago - GlobeNewsWire

Cabaletta Bio to Present at the Jefferies Healthcare Conference

PHILADELPHIA, May 31, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...

1 year ago - GlobeNewsWire

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first c...

1 year ago - GlobeNewsWire

TipRanks reveals the top 10 health care sector analysts of the past decade

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

1 year ago - CNBC

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first c...

1 year ago - GlobeNewsWire

Cabaletta Bio Announces Proposed Public Offering of Common Stock

PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first c...

1 year ago - GlobeNewsWire

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

–  Phase 1/2 trial for CABA-201 planned to initiate in patients with myositis at an initial dose that is equivalent to the dose used in a patient with myositis as reported in the recent Lancet Rheumat...

1 year ago - GlobeNewsWire

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

– IND application cleared within 30 days for clinical trial of CABA-201 in patients with LN and SLE and Fast Track Designation granted by the FDA for CABA-201 to deplete CD19-positive B cells and impr...

1 year ago - GlobeNewsWire

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...

1 year ago - GlobeNewsWire